Lexicon Pharmaceuticals (NASDAQ:LXRX) will issue its quarterly earnings data before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $28.52 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $13.26 million. The business’s revenue was down 63.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.40) EPS. On average, analysts expect Lexicon Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
LXRX traded down $0.23 during trading on Wednesday, hitting $1.43. The stock had a trading volume of 23,979 shares, compared to its average volume of 348,841. The stock has a market capitalization of $176.41 million, a price-to-earnings ratio of -1.25 and a beta of 0.84. Lexicon Pharmaceuticals has a 12 month low of $1.46 and a 12 month high of $12.17. The company has a 50 day simple moving average of $5.73.
LXRX has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. ValuEngine downgraded shares of Wolverine World Wide from a “hold” rating to a “sell” rating in a report on Monday, May 20th. BidaskClub downgraded shares of Westport Fuel Systems from a “buy” rating to a “hold” rating in a report on Friday, July 19th. Citigroup lifted their target price on shares of Visteon from $58.00 to $69.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Wedbush set a $175.00 target price on shares of Lululemon Athletica and gave the stock a “hold” rating in a report on Tuesday, June 11th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $12.13.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.